PRKCQ and neoplasm: Moreover, the consequences of PRKCQ inhibition on the tumor immune microenvironment may be favorable, as suggested by the results with an inhibitor of LSD1, a downstream target of PRKCQ [17]; LSD1 inhibition enhanced recruitment of M1 type macrophages that could favorably contribute to anti-tumor immunity.